Sanofi announces changes to its Executive Committee

Media Update: New data at ERS showcases Sanofi's scientific leadership in addressing unmet needs across a variety of respiratory conditions 


Media Update: New data at ERS showed Xenpozyme® (olipudase alfa) improved respiratory functions in adults with ASMD


Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change


Availability of the Q3 2023 Memorandum for modelling purposes


Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A